Xofigo

Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
CRPC document aids in complex decisionsIn its current iteration, the AUA's CRPC guideline contains 20 statements relating to treatments for six index patients defined by the presence or absence of metastatic disease, presence and degree of symptoms, ECOG performance status, and prior treatment with docetaxel (Taxotere) along with two statements on the use of preventive treatments for bone health.
Concomitant Ra 223, abiraterone found safe, effectiveRadium 223 dichloride (Ra 223 [Xofigo]) can be safely combined with abiraterone acetate (ZYTIGA) for the treatment of patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases, and appears to result in decreased bone pain and improved quality of life, according to the interim results of an open-label prospective study known as eRADicAte.
Prognostic factors identified in patients taking PCa TxAnalyses of overall survival rates among subgroups of men who received radium-223 dichloride (Ra 223; Xofigo) as part of an expanded access program suggest factors that may have prognostic significance, including effects of prior and concomitant treatments.
mCRPC advances come with choices, challengesIn this article, Robert A. Dowling, MD, examines some of the practice-related implications of the rapid change in the management of patients with advanced prostate cancer.
No impact on PCa agent following bankruptcy filingDendreon Corp., the maker of sipuleucel-T (Provenge), said it expects no impact on access to the prostate cancer immunotherapy following the company’s Chapter 11 filing last week.
Approval of enzalutamide pre-chemo a ‘game changer’
Approval of enzalutamide pre-chemo a ‘game changer’The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
Urology Product Preview May 2014Drugs and devices in the pipeline from MEI Pharma, Bayer HealthCare, Merck, Pfizer, and Minomic International.
Advanced prostate cancer research focuses on newer agents for mCRPCResearch in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
Collaboration urged for advanced prostate cancer careWith a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.